What is off-label prescribing and when does it affect claims?
Understanding off-label use, when it's appropriate, and what it means for your insurance liability.
Published: 3 April 2026 | Updated: 3 April 2026
Defining Off-Label Prescribing
Off-label prescribing occurs when a doctor prescribes a medication for a use that the regulatory body (TGA in Australia, MEDSAFE in New Zealand) hasn't specifically approved. The medication is approved, but the indication is not. A drug approved for depression might be prescribed off-label for anxiety. A medication approved for seizures might be prescribed off-label for nerve pain. A cancer drug might be prescribed off-label for a rare condition where no other treatment exists.
This happens frequently in clinical practice. It's not necessarily inappropriate. Sometimes off-label use is evidence-based, supported by clinical research, and represents best practice. Sometimes it's necessary because approved alternatives don't exist or have failed. Sometimes it's questionable, lacking clear evidence but prescribed anyway.
For your claims, off-label prescribing raises specific questions: Is this use supported by clinical evidence? Did the patient consent to off-label use? If complications occur, does the lack of official approval affect liability? Is the insurer on the hook for a use that regulators never formally approved?
Why Doctors Prescribe Off-Label
Understanding the reasoning helps you assess whether off-label use in your claims is reasonable or questionable.
Evidence-Based Off-Label Use
Strong clinical evidence supports using medication X for indication Y, but formal regulatory approval hasn't been obtained (often because the drug is older, off-patent, or the manufacturer didn't seek approval for that use). A doctor prescribes low-dose tricyclic antidepressants for neuropathic pain because research clearly demonstrates benefit. This is evidence-based off-label use and is generally defensible.
Guideline-Supported Off-Label Use
Major clinical guidelines recommend using a medication off-label for a specific condition based on accumulated research. A cardiologist prescribes an ACE inhibitor off-label after a heart attack, following established cardiology guidelines. This represents appropriate practice supported by professional bodies.
No-Approved-Alternative Off-Label Use
Your claimant has a rare condition. No TGA-approved medication exists for this condition, but evidence suggests a medication approved for a similar condition might help. The doctor prescribes off-label because it's the only option. This is often medically necessary and defensible.
Clinical Experience Off-Label Use
The doctor has experience with a medication and believes it will help, but limited evidence exists. A specialist prescribes an anticonvulsant off-label for a rare condition based on their clinical judgment and prior cases. This might be defensible depending on the strength of their experience and reasoning.
Questionable Off-Label Use
A medication is prescribed off-label without supporting evidence, guidelines, or clinical necessity. A doctor prescribes an expensive, potent medication off-label for a mild condition when approved, cheaper alternatives exist. If complications occur, this becomes a liability concern for your insurer.
Off-Label Use and Insurance Liability
When your claimant suffers a complication from off-label medication use, questions arise. Did the prescriber obtain informed consent? Were alternatives considered? Was this use supported by clinical evidence or professional guidelines? If the answer to any of these is no, your insurer's exposure increases.
Off-label use isn't automatically negligent. But it's a red flag that prompts scrutiny. If your claimant had an adverse outcome from questionable off-label use, a court might find that the prescriber failed in their duty of care. The fact that regulators haven't approved this indication becomes relevant.
| Off-Label Use Type | Evidence Base | Liability Risk | Defensibility |
|---|---|---|---|
| Evidence-based (RCTs support use) | Strong | Low | Highly defensible |
| Guideline-recommended | Strong | Low | Highly defensible |
| No approved alternative exists | Variable | Low-Moderate | Defensible if necessary |
| Clinical judgment-based | Weak | Moderate | Potentially defensible |
| Questionable without evidence | None | High | Difficult to defend |
Off-Label Use in Common Insurance Scenarios
Neuropathic Pain: Appropriate Off-Label Use
Your claimant has post-injury nerve pain. The doctor prescribes gabapentin, which is TGA-approved for other conditions but not specifically approved for neuropathic pain in your claimant's context. However, clinical guidelines specifically recommend gabapentin for neuropathic pain. This is evidence-based, guideline-supported off-label use and is entirely appropriate. If your claimant improves, this was the right decision. If complications occur, you're on solid ground: the prescriber followed guidelines and offered evidence-based treatment.
Mental Health: Mixed Appropriateness
Your claimant with injury-related anxiety is prescribed a medication originally developed for depression but increasingly used off-label for anxiety. Evidence supports this use. Clinical guidelines recommend it. The doctor obtained informed consent. This is defensible off-label prescribing. Contrast this with a doctor prescribing an experimental psychiatric medication off-label for mild anxiety when approved, safer alternatives exist. That raises liability concerns.
Rare Condition: Necessary Off-Label Use
Your claimant has a rare post-injury complication. No approved treatment exists. The specialist prescribes a medication off-label based on pathophysiology and case reports. The doctor documents the reasoning, discusses it with the claimant, and obtains consent. If it helps, it's a reasonable medical decision. If complications occur, the fact that you tried a necessary treatment in the absence of approved alternatives is defensible.
Cost-Driven Off-Label Use: Higher Risk
Your claimant is on an approved medication that works well but is expensive. The doctor switches to a cheaper off-label alternative without clinical evidence supporting this use for your claimant's condition. If the off-label medication causes problems, your insurer's position weakens significantly. The prescriber prioritized cost over evidence-based care, and regulatory approval wasn't obtained for this indication for good reason.
Recognizing Off-Label Use in Your Claims
When reviewing a claimant's medications, how do you identify off-label use? The medication name doesn't tell you. You need to know the indication for which it was prescribed and cross-reference the TGA approval. Some high-risk medication-indication combinations appear frequently:
- Anticonvulsants for pain conditions (off-label but often evidence-based)
- Antidepressants for anxiety (off-label but guideline-supported)
- Atypical antipsychotics for behavioral symptoms in non-psychotic conditions (variable evidence)
- Muscle relaxants for conditions other than those approved (often off-label)
- Anticonvulsants for mood disorders (off-label but guideline-supported in some cases)
The presence of off-label use alone doesn't indicate a problem. But it flags the need to ask: Is this use evidence-based? Are guidelines available that support it? Were alternatives considered? Did informed consent occur? A medication review helps answer these questions.
Assessing Off-Label Use in Your Claims
When off-label prescribing is identified, a pharmacist review assesses: What evidence supports this use? Do clinical guidelines recommend it? Has the patient been informed of off-label status? Are there approved alternatives? Is this use evidence-based and defensible, or does it represent questionable prescribing? This assessment protects your insurer by identifying defensible off-label use versus risky prescribing decisions.
Informed Consent and Off-Label Use
If off-label use is to be defensible, informed consent matters. The prescriber should ideally have discussed with your claimant that the medication isn't approved for their specific condition but that research and clinical experience support its use for their situation. If complications arise, the fact that consent was obtained becomes important.
In practice, many off-label prescriptions occur without explicit discussion of the off-label nature. When complications emerge and your insurer investigates, the absence of documented consent becomes problematic. It suggests the prescriber didn't consider the need for consent or didn't think the off-label use was significant enough to discuss.
The Bottom Line
Off-label prescribing is common and often appropriate. But it creates specific liability considerations for insurers. Evidence-based, guideline-supported off-label use is defensible. Off-label use without evidence or alternatives is not. When your claimant experiences complications from off-label medication use, your insurer's exposure depends on whether that use was evidence-based and whether informed consent occurred. Medication reviews identify off-label use and assess its defensibility, protecting your claims.
Identify questionable off-label prescribing before it becomes a liability.
If your claimants are receiving medications for unapproved indications, you need to know whether that use is evidence-based and defensible. IMM's pharmacist reviews assess the appropriateness of off-label use and identify potential liability risks.
Request a Medication Review
